Apolipoprotein A1 Polymorphisms and Risk of Coronary Artery Disease: a Meta-analysis

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2017 Jul 20

PMID 28721149

Citations 13

Authors

Lang-Biao Xu

Ya-Feng Zhou

Jia-Lu Yao

Si-Jia Sun

Qing Rui

Xiang-Jun Yang

Xiao-Bo Li

Affiliations

Soon will be listed here.

Abstract

Introduction: It has been reported that APOA1 -75G/A polymorphism might be associated with susceptibility to coronary artery disease (CAD). Owing to mixed and inconclusive results, we conducted a meta-analysis to systematically summarize and clarify the association between APOA1-75G/A polymorphism and the risk of CAD.

Material And Methods: A systematic search of studies on the association of single nucleotide polymorphisms (SNP) with susceptibility to CAD was conducted. A total of 9 case-control studies (1864 cases and 1196 controls) on the APOA1-75G/A polymorphism were included.

Results: We observed no statistically significant association between APOA1 -75G/A polymorphism and risk of CAD under the dominant genetic model (AA + AG vs. GG: OR = 1.03, 95% CI: 0.65-1.66), allelic contrast (A vs. G: OR = 0.88, 95% CI: 0.58-1.32), heterozygote model (AG vs. GG: OR = 1.24, 95% CI: 0.81-1.89) or homozygote model (AA vs. GG: OR = 0.52, 95% CI: 0.26-1.05). Significant heterogeneity between individual studies appears in all five models, but a strong association under the recessive genetic model (AA vs. AG + GG: OR = 0.51, 95% CI: 0.28-0.92). In the subgroup analysis by Hardy-Weinberg equilibrium (HWE; the presence or absence of HWE in controls), significantly decreased CAD risk and no significant heterogeneity were observed among controls consistent with HWE. Overall, the APOA1 A allele is one of the protective factors of CAD. A stronger association between APOA1-75G/A polymorphisms and CAD risk was present in the studies consistent with HWE.

Conclusions: The minor allele of the APOA1-75G/A polymorphism is a protective factor for CAD, especially in the studies consistent with HWE.

Citing Articles

Emerging Biomarkers and Determinants of Lipoprotein Profiles to Predict CVD Risk: Implications for Precision Nutrition.

Andersen C, Fernandez M Nutrients. 2025; 17(1.

PMID: 39796476 PMC: 11722654. DOI: 10.3390/nu17010042.

Dysfunctional High-Density Lipoprotein Cholesterol and Coronary Artery Disease: A Narrative Review.

Madaudo C, Bono G, Ortello A, Astuti G, Mingoia G, Galassi A J Pers Med. 2024; 14(9).

PMID: 39338250 PMC: 11432852. DOI: 10.3390/jpm14090996.

Interaction between genetic risk score and dietary fat intake on lipid-related traits in Brazilian young adults.

Wuni R, Amerah H, Ammache S, Cruvinel N, da Silva N, Kuhnle G Br J Nutr. 2024; 132(5):575-589.

PMID: 39308196 PMC: 11536265. DOI: 10.1017/S0007114524001594.

Gene Cluster at 11q23.3 and Lipid Metabolism Disorders: From Epigenetic Mechanisms to Clinical Practices.

Xiao Q, Wang J, Wang L, Ding H Biomedicines. 2024; 12(6).

PMID: 38927431 PMC: 11201263. DOI: 10.3390/biomedicines12061224.

Novel lipid biomarkers and associated gene polymorphism in young ST-segment elevation myocardial infarction.

Muheeb G, Gupta M, Kunal S, Basia D, Mp G, Bansal A Indian Heart J. 2022; 75(1):68-72.

PMID: 36574567 PMC: 9986731. DOI: 10.1016/j.ihj.2022.11.014.

References

Dunn J, Ipsen J, Elsom K, Ohtani M . Risk factors in coronary artery disease, hypertension and diabetes. Am J Med Sci. 1970; 259(5):309-22. DOI: 10.1097/00000441-197005000-00002. View

Ding Y, Zhu M, Wang Z, Zhu J, Feng J, Li D . Associations of polymorphisms in the apolipoprotein APOA1-C3-A5 gene cluster with acute coronary syndrome. J Biomed Biotechnol. 2012; 2012:509420. PMC: 3366243. DOI: 10.1155/2012/509420. View

Zou J, Ma Y, Xie X, Yang Y, Pan S, Adi D . The association between CYP1A1 genetic polymorphisms and coronary artery disease in the Uygur and Han of China. Lipids Health Dis. 2014; 13:145. PMC: 4175619. DOI: 10.1186/1476-511X-13-145. View

SCHAEFER L, NECHEMIAS C . ENDOGENOUS HORMONES, LIPID METABOLISM, AND CORONARY ARTERY DISEASE. Prog Cardiovasc Dis. 1965; 7:449-64. DOI: 10.1016/s0033-0620(65)80038-x. View

Rai T, Khullar M, Sehrawat B, Ahuja M, Sharma P, Vijayvergiya R . Synergistic effect between apolipoprotein E and apolipoprotein A1 gene polymorphisms in the risk for coronary artery disease. Mol Cell Biochem. 2008; 313(1-2):139-46. DOI: 10.1007/s11010-008-9751-3. View

van Hateren K, Bilo H . Hypertension control and cardiovascular outcomes among patients with diabetes and coronary artery disease. JAMA. 2010; 304(15):1672. DOI: 10.1001/jama.2010.1464. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Otocka-Kmiecik A, Mikhailidis D, Nicholls S, Davidson M, Rysz J, Banach M . Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?. Prog Lipid Res. 2012; 51(4):314-24. DOI: 10.1016/j.plipres.2012.03.003. View

Groenendijk M, Cantor R, de Bruin T, Dallinga-Thie G . The apoAI-CIII-AIV gene cluster. Atherosclerosis. 2001; 157(1):1-11. DOI: 10.1016/s0021-9150(01)00539-1. View

10.

Nikolic D, Rizzo M, Mikhailidis D, Wong N, Banach M . An evaluation of RVX-208 for the treatment of atherosclerosis. Expert Opin Investig Drugs. 2015; 24(10):1389-98. DOI: 10.1517/13543784.2015.1083010. View

11.

Ballantyne C, Hoogeveen R . Role of lipid and lipoprotein profiles in risk assessment and therapy. Am Heart J. 2003; 146(2):227-33. DOI: 10.1016/S0002-8703(02)94701-0. View

12.

Wei X, Lin Y, Yang X, Lian D, Chen J, Yu D . [Association between apolipoprotein A1-75 bp gene polymorphisms and risk for dyslipidemia and coronary artery disease]. Zhonghua Xin Xue Guan Bing Za Zhi. 2015; 42(11):916-21. View

13.

Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y . Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 1997; 95(8):2032-6. DOI: 10.1161/01.cir.95.8.2032. View

14.

Li X, Hong L, Luo S, Guo Y, Zhu C, Sun J . Impact of admission triglyceride for early outcome in diabetic patients with stable coronary artery disease. Lipids Health Dis. 2014; 13:73. PMC: 4013537. DOI: 10.1186/1476-511X-13-73. View

15.

Wilson P, Abbott R, CASTELLI W . High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 1988; 8(6):737-41. DOI: 10.1161/01.atv.8.6.737. View

16.

Turner R, Millns H, Neil H, Stratton I, Manley S, Matthews D . Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998; 316(7134):823-8. PMC: 28484. DOI: 10.1136/bmj.316.7134.823. View

17.

Saha N, Tay J, Low P, Humphries S . Guanidine to adenine (G/A) substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI levels in Chinese non-smokers. Genet Epidemiol. 1994; 11(3):255-64. DOI: 10.1002/gepi.1370110304. View

18.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

19.

Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Karetnikova V, Shilov A . Multivessel coronary artery disease, free fatty acids, oxidized LDL and its antibody in myocardial infarction. Lipids Health Dis. 2014; 13:111. PMC: 4098672. DOI: 10.1186/1476-511X-13-111. View

20.

Gordon D, Probstfield J, Garrison R, Neaton J, CASTELLI W, Knoke J . High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989; 79(1):8-15. DOI: 10.1161/01.cir.79.1.8. View